These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 17374091)

  • 1. Vascular calcification--a new window on the cardiovascular system: role of agents used to manipulate skeletal integrity.
    Covic A; Gusbeth-Tatomir P; Goldsmith DJ
    Semin Dial; 2007; 20(2):158-69. PubMed ID: 17374091
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effect of non-calcium-based phosphate binders on vascular calcifications in patients on hemodialysis: clinical experience and hypotheses].
    Bolasco P
    G Ital Nefrol; 2011; 28(4):357. PubMed ID: 21809303
    [No Abstract]   [Full Text] [Related]  

  • 3. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
    Sprague SM
    Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].
    Koizumi M; Fukagawa M
    Clin Calcium; 2010 Nov; 20(11):1700-8. PubMed ID: 21037391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular calcification and disordered mineral metabolism in dialysis patients.
    Kalpakian MA; Mehrotra R
    Semin Dial; 2007; 20(2):139-43. PubMed ID: 17374088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sevelamer treatment on cardiovascular abnormalities in mice with chronic renal failure.
    Maizel J; Six I; Dupont S; Secq E; Dehedin B; Barreto FC; Benchitrit J; Poirot S; Slama M; Tribouilloy C; Choukroun G; Mazière JC; Drueke TB; Massy ZA
    Kidney Int; 2013 Sep; 84(3):491-500. PubMed ID: 23594676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Management of secondary hyperparathyroidism].
    Cunningham J
    Clin Calcium; 2005 Sep; 15 Suppl 1():217-24. PubMed ID: 16279027
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis.
    Takei T; Otsubo S; Uchida K; Matsugami K; Mimuro T; Kabaya T; Akiba T; Nitta K
    Nephron Clin Pract; 2008; 108(4):c278-83. PubMed ID: 18434749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer?
    Negri AL
    J Nephrol; 2010; 23(6):653-7. PubMed ID: 20349415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is combined calcium/magnesium phosphate binder really noninferior to sevelamer hydrochloride?
    Spasovski G; Vanholder R
    Nephrol Dial Transplant; 2011 Apr; 26(4):1442-3; author reply 1443-4. PubMed ID: 21339309
    [No Abstract]   [Full Text] [Related]  

  • 11. Nonphosphate-binding effects of sevelamer--are they of clinical relevance?
    Marangon N; Lindholm B; Stenvinkel P
    Semin Dial; 2008; 21(5):385-9. PubMed ID: 18573137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. After several years of witchhunting, can calcium-based phosphate binding be released on probation?
    Ketteler M; Biggar P
    Nephrol Dial Transplant; 2008 Jan; 23(1):17-9. PubMed ID: 18039641
    [No Abstract]   [Full Text] [Related]  

  • 13. Ten-year experience with sevelamer and calcium salts as phosphate binders.
    Raggi P; Vukicevic S; Moysés RM; Wesseling K; Spiegel DM
    Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S31-40. PubMed ID: 20089501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Final Word: The binders wars 2007-2017: "The truth is out there somewhere...".
    Covic A; Goldsmith DJ
    Semin Dial; 2007; 20(2):170-1. PubMed ID: 17374092
    [No Abstract]   [Full Text] [Related]  

  • 15. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.
    Brandenburg VM; Schlieper G; Heussen N; Holzmann S; Busch B; Evenepoel P; Vanholder R; Meijers B; Meert N; Fassbender WJ; Floege J; Jahnen-Dechent W; Ketteler M
    Nephrol Dial Transplant; 2010 Aug; 25(8):2672-9. PubMed ID: 20172849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving phosphate-binder therapy as a way forward.
    Hutchison AJ
    Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i19-24. PubMed ID: 15126650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relationship between sevelamer HCl and vascular calcification].
    Uemura K; Kakuta T; Saito A
    Clin Calcium; 2007 Mar; 17(3):392-8. PubMed ID: 17339744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [K-DOQI guidelines for calcium and phosphorus metabolism in chronic kidney disease: outcomes, compliance and new drugs for treatment].
    Negri AL
    Nefrologia; 2007; 27(6):670-3. PubMed ID: 18336094
    [No Abstract]   [Full Text] [Related]  

  • 19. Phosphate binders and management of hyperphosphataemia in end-stage renal disease.
    Savica V; Calò LA; Monardo P; Santoro D; Bellinghieri G
    Nephrol Dial Transplant; 2006 Aug; 21(8):2065-8. PubMed ID: 16766546
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pathogenesis and treatment of vascular calcification in CKD].
    Brancaccio D; Gallieni M; Pasho S; Fallabrino G; Olivi L; Volpi E; Ciceri P; Missaglia E; Ronga C; Brambilla C; Butti A; Rocca-Rey L; Chiarelli G; Cozzolino M
    G Ital Nefrol; 2009; 26 Suppl 45():S20-7. PubMed ID: 19382090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.